CHITTARANJAN NATIONAL CANCER INSTITUTE
To develop new drugs in collaboration with Pharmaceutical Industry.
A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine and Prednisone vs. MabThera® plus Cyclophosphamide, Vincristine, Prednisone, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma.
Sponsors: – Hexal AG, a Sandoz CompanyPrincipal Investigator: – Dr. Kalyan Kusum MukherjeeCo-Investigators: –Dr. Suparna MazumderDr. Indranil GhoshDr. Partha NathDr. Durga Prasad NandaChief Study Co-ordinator:Subhabrata DeyStudy Co-ordinators: Somnath ChakrabortyPhlebotomist: Surya Kanta Roy.Status: Ongoing.No. of Patient Recruited: 2No. of Patient Screened Failure: 2
A Multicenter, Open-Label, Randomized, Phase-II Study to Evaluate the Efficacy and Safety of NKTR 102 (PEG- Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Patients with Metastatic Colorectal Cancer (mCRC) (Study Code: 08-PIR-03).
Status: Ongoing.No. of Patient Recruited: 16No. of Patient Screened Failure: 2
An Open Label, Balanced, Randomized, Multicentre, Multiple-Dose, Two-Period, Two-Treatment, Two-Sequence, Steady State, Crossover Comparative Bioequivalence Study of Two Formulations of 6 – Mercaptopurine in Adult Subjects with Acute Lymphoblastic Leukaemia (ALL). (Study Code: 19960001)
Sponsors: Orion Corporation, Orion Pharma, P.O. Box 425, FI- 20101, Turku, Finland.Principal Investigator: Dr. Kalyan Kusum MukherjeeCo-Investigators: Dr. Partha Nath, Dr. Durga Prasad NandaChief Study Co-ordinator: Subhabrata DeyStudy Co-ordinator: Somnath Chakraborty, Moumita Banerjee
Phlebotomist: Surya Kanta RoyStatus: Ongoing.No. of Patient Recruited: 0No. of Patient Screened Failure: 1
An Open Label Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy. (Study Code: 113-10)
Sponsors: Intas Pharmaceuticals Ltd.2nd Floor, Chinubhai Center, Ashram Road., 2nd Floor, Chinubhai Center, Ashram Road.Principal Investigator: Dr. Kalyan Kusum MukherjeeCo-Investigators: Dr. Partha Nath, Dr. Durga Prasad Nanda, Dr. Indranil GhoshChief Study Co-ordinator: Subhabrata DeyStudy Co-Ordinator: Somnath Chakraborty, Moumita Banerjee, Moumita Banerjee.Phlebotomist: Surya Kanta RoyStatus: Ongoing.No. of Patient Recruited: 13No. of Patient Screened Failure: 1